Print

Featured Event...


ChinaBio® Partnering Forum 2012

May 23-24, 2012 | Suzhou, China
 Register now and save up to $ 200!
ChinaBio® LLC and EBD Group will host their fourth ChinaBio® Partnering Forum in China to meet the needs of biotech and pharma companies as well as developers of early stage technology looking for funding and strategic partnerships. ChinaBio® Partnering Forum is the largest partnering conference in China, drawing more than 700 delegates and 400 companies from all over the world in 2012. Companies and researchers with novel technologies interested in partnering their technologies or products, initiating strategic alliances, or tapping into the global financing network are welcome to apply to present. With over one-third of the attendees being C-level decision makers, ChinaBio® Partnering Forum is the event to get partnerships started in China.

To find out more about presenting to international pharma, click here!

>> See  http://www.cbpf2012.com/ for more information.

 New!  Top Stories


WuXi PharmaTech and ShangPharma Are M&A Targets: Bloomberg | Feb 3, 2012 

China Excitement at J.P. Morgan Healthcare Conference | Jan 15, 2012 

China Announces Major Program for Biotechnology 2010-2020 | Jan 6, 2012 

Merck Will Build Beijing R&D Center; Invest $1.5 Billion in China | Dec 6, 2011 

China's 12th Five-year Plan for Medical Technology | Dec 2, 2011

>> See all top stories...

Recent Articles

First event iApply to present now! Deadline: April 30

Recent Articles

  Changchun BCHT Biotech Acquires Flu Vaccine Technology (in: Deals & Financings)
Feb 10, 2012
Changchun BCHT Biotechnology obtained an exclusive license for a live attenuated influenza (LIAV) vaccine technology from BioDiem, an Australian vaccine company. The license gives BCHT exclusive China rights to the technology for an egg-based production method in pandemic and seasonal influenza vaccines. Although the license is limited to LAIV for private market vaccines, BCHT holds a second license to LAIV for China’s public market in China via a sub-license from the World Health Organization. More details....

Share this with colleagues:  

  Shanghai Pharma to Spend $80 Million on North China Expansion (in: Deals & Financings)
Feb 9, 2012
Shanghai Pharmaceuticals announced a plan to set up a Beijing headquarters for North China. The company will establish a new entity, which will be called Shanghai Pharma Northern Investment Co., Ltd. and capitalized with $80 million. According to the company, Shanghai Pharma Northern will coordinate the company’s various subsidiaries in the region and take responsibility for further investment in North China. More details....

Stock Symbol: (SHA: 601607; HKEX: 02607)

Share this with colleagues:  

  Takeda Sets Up China Division to Supervise Clinical Trials (in: News & Analysis)
Feb 9, 2012
Takeda Pharma has established a new China division, Takeda Shanghai Development Center, which will be put in charge of the company’s clinical development projects in Asia. The TSDC will concentrate on general medicine in China and oncology for all of Asia. It will conduct clinical trials – increasing the emphasis on China – and it will also be given the task of deepening relationships with physicians and drug regulators. More details....

Stock Symbol: (TO: 4502)

Share this with colleagues:  

  Once Again, Fosun Pharma Plans Hong Kong IPO (in: Deals & Financings)
Feb 8, 2012
Shanghai Fosun Pharma's on-again/off-again Hong Kong IPO is apparently now scheduled to take place early this year. According to an unnamed insider, the company has filed its listing application with the Hong Kong exchange. Fosun hopes to raise between $600 million and $800 million by floating up to a 20% stake in the company. More details....

Stock Symbol: (SHA: 600196)

Share this with colleagues:  

  Shanghai Biochip Signs MOU with GeneNews of Canada (in: Deals & Financings)
Feb 7, 2012
Shanghai Biochip, also known as ShanghaiBio Corp.,signed an MOU with GeneNews Limited, a Canadian molecular diagnostics company. The agreement calls for GeneNews and SBC to set up a Sentinel Center for Personalized Medicine in China, based on GeneNews’ Sentinel technology. The Center will seek to co-develop and commercialize molecular diagnostic products. Also, SBC will gain non-exclusive rights to market and sell GeneNews' ColonSentry™ test in China. More details....

Share this with colleagues:  

  Nanjing Pharma’s Weak Financials Spark Takeover Talk (in: Deals & Financings)
Feb 7, 2012
Nanjing Pharmaceutical, a company that makes and distributes pharmaceuticals, announced it will report a loss for 2011. The company blamed the loss on higher interest payments on its $387 million of debt. Nanjing Pharma is the largest drug distributor in China’s eastern provinces of Jiangsu, Anhui and Fujian. The combination of lower valuation and leading market position sparked speculation that one of China’s major drug distribution companies will make a bid for Nanjing Pharma.. More details....

Stock Symbol: (SHA: 600713)

Share this with colleagues:  

  Shanghai Pharma Acquires Second API Maker this Year (in: Deals & Financings)
Feb 6, 2012
Shanghai Pharmaceuticals will buy Changzhou Kony Pharm Co., a company that makes APIs for antivirals and cardiovascular drugs. Shanghai Pharma positioned the acquisition as mutually advantageous. It is also a way for Shanghai Pharma to put some of the $2 billion garnered from its Hong Kong IPO to work. Although the price was not disclosed, Kony Pharma was estimated to be worth about 300 million RMB ($47.6 million). . In January, Shanghai Pharma purchased a 51% share in Jinhe Bio-Technology, a company that specializes in APIs for cancer drugs. More details....

Stocik Symbol: (SHA: 601607.SH; HK: 02607)

Share this with colleagues:  

  The Week in Review: Are WuXi PharmaTech and ShangPharma Takeover Targets? (in: Week in Review)
Feb 4, 2012
WuXi PharmaTech and ShangPharma are both attractive M&A targets, with higher profit margins and lower PE ratios than their US competitors; Cardinal Health will make $90 million in China acquisitions to bolster its drug distribution coverage; Tianjin Tasly Pharma and SemBioSys Genetics of Canada received business licenses for their China JV; Transgene formed a scientific cooperation program with three European institutions and Fudan University Shanghai Cancer Center; the Beijing FDA added new categories of drugs for fast-track status; Steve Yang, AstraZeneca’s VP for R&D in Asia, says the company’s China R&D operation aims to “transform how we do R&D;” AstraZeneca announced another 7,300 layoffs in the US and Europe as it adds activities in China; and Frontage Labs announced its completed a Phase I trial of a China botanical drug in the US. More details….

Stock Symbols: (NYSE: WX) (NYSE: SHP) (NYSE: CAH) (SHA: 600535) (TSX: SBS) (Euronext: TNG) (NYSE: AZN)

Share this with colleagues:  

  Steve Yang: AstraZeneca in China Wants to Transform Pharma R&D Models (in: Featured Companies)
Feb 3, 2012
Steve Yang, AstraZeneca’s high profile VP and Head of R&D for Asian and Emerging Markets, is setting an ambitious goal for the company’s China R&D operation: “We will try to innovate and transform how we do R&D,” said Yang in a McKinsey Quarterly interview. Because innovative pharma development is still new in China, “we are starting with a clean slate,” he added. “But that could be an opportunity,” given that established ways of doing drug R&D are not institutionalized, leaving China free to map its own path. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  

  Cardinal Health Plans $90 Million in China Acquisitions (in: Deals & Financings)
Feb 3, 2012
Cardinal Health, the US-based drug distributor, plans to make $90 million in China acquisitions to bolster its geographic coverage in mainland China. In addition, Cardinal said it is expanding its China product offerings to include medical products, lab equipment and other supplies. Earlier, Cardinal had announced a plan to make acquisitions, but it now seems to have made deals, though it hasn't released any specifics. More details....

Stock Symbol: (NYSE: CAH)

Share this with colleagues:  

 
more articles >>